Drugs / 68Ga-PSMA-R2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03490032 | May 2018 → Aug 2019 | metastatic prostate carcinoma | Advanced Accelerator Applications | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-PSMA-R2 | “Conclusion: 68Ga-PSMA-R2 was well tolerated, with no drug-related treatment-emergent adverse events. Safety and preliminary imaging performance data support further development...” PMID 39915126 ↗ Mar 2025 |
| Modality | Diagnostic / imaging agent | “as a diagnostic agent” PMID 39915126 ↗ Mar 2025 |
| Route | Intravenous | “Subjects received a single dose of 3 MBq/kg, (\>=150 and =\<250 MBq), of 68\^Ga-PSMA-R2 intravenously.” NCT03490032 ↗ |